首页> 外文期刊>Human Reproduction >Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp
【24h】

Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp

机译:多囊卵巢综合征女性在正常血糖-高胰岛素血症钳夹下具有固有的胰岛素抵抗

获取原文
获取原文并翻译 | 示例
           

摘要

Study Question: What is the prevalence of insulin resistance (IR) and the contributions of intrinsic and extrinsic IR in women diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria? Summary Answer: We report novel clamp data in Rotterdam diagnosed PCOS women, using World Health Organization criteria for IR showing that women with PCOS have a high prevalence of IR, strengthening the evidence for an aetiological role of IR in both National Institutes of Health (NIH) and Rotterdam diagnosed PCOS in lean and overweight women. What is Known Already: PCOS is a complex endocrine condition with a significant increased risk of gestational diabetes and type 2 diabetes. Study Design , Size, Duration Using a cross-sectional Study Design , 20 overweight and 20 lean PCOS (Rotterdam criteria), 14 overweight and 19 lean body mass index (BMI)-matched control non-PCOS women underwent clinical measures of IR after a 3-month withdrawal of insulin sensitizers and the oral contraceptive pill.MATERIALS, SETTING, METHODSIn an academic clinic setting, glucose infusion rate (GIR) on euglycaemic-hyperinsulinaemic clamp was investigated as a marker of insulin sensitivity. Main Results and the Role of Chance: PCOS women were more IR than BMI-matched controls (main effect for BMI and PCOS; P 0.001). IR was present in 75% of lean PCOS, 62% of overweight controls and 95% of overweight PCOS. Lean controls (mean ?? SD; GIR 339 ?? 76 mg min-1 m-2) were less IR than lean PCOS (270 ?? 66 mg min-1 m-2), overweight controls (264 ?? 66 mg min-1 m-2) and overweight PCOS (175 ?? 96 mg min-1 m-2). The negative relationship between BMI and IR reflected by GIR was more marked in PCOS (y = 445.1-7.7x, R2 = 0.42 (P 0.0001) than controls (y = 435.5-4.6x, R2 = 0.04 (P 0.01)). Limitations, Reasons For Caution The study did not use glucose tracer techniques to completely characterize the IR, as well as the lack of matching for body composition and age. Wider Implications of the Finding: s: IR is exacerbated by increased BMI, supporting intrinsic IR in PCOS. BMI impact on IR is greater in PCOS, than in controls, irrespective of visceral fat, prioritizing lifestyle intervention and the need for effective therapeutic interventions to address intrinsic IR and prevent diabetes in this high-risk population. Study Funding/Competing Interes: T(S)This investigator-initiated trial was supported by grants from the National Health & Medical Research Council (NHMRC) Grant number 606553 (H.J.T., N.K.S. and S.K.H.) as well as Monash University and The Jean Hailes Foundation. H.J.T. is an NHMRC Research Fellow. N.K.S. is supported through the Australian Government's Collaborative Research Networks (CRN) programme. A.E.J. is a Jean Hailes and NHMRC scholarship holder. The authors declare that there is no conflict of interest associated with this manuscript. Clinical Trial Registrationisrctn 84763265. ? 2013 The Author.
机译:研究问题:根据鹿特丹标准,诊断为多囊卵巢综合征(PCOS)的女性中胰岛素抵抗(IR)的患病率以及内源性和外源性IR的作用是什么?总结答案:我们使用世界卫生组织的IR标准报告了鹿特丹诊断为PCOS的女性的新颖钳位数据,结果显示PCOS妇女的IR患病率很高,这加强了IR在两个国家卫生研究院(NIH)中的病因作用的证据)和鹿特丹诊断为瘦弱和超重女性的PCOS。已经知道的是:PCOS是一种复杂的内分泌疾病,其妊娠糖尿病和2型糖尿病的风险显着增加。研究设计,规模,持续时间采用横断面研究设计,对20例超重和20瘦PCOS(鹿特丹标准),14例超重和19瘦体重指数(BMI)匹配的对照非PCOS妇女进行了临床测量。停用胰岛素敏化剂和口服避孕药3个月。材料,地点,方法在一个学术诊所中,研究了在正常血糖-高胰岛素血症钳夹上的葡萄糖输注速率(GIR)作为胰岛素敏感性的指标。主要结果和机会的作用:PCOS妇女比BMI匹配的对照组的IR更高(对BMI和PCOS的主要影响; P <0.001)。瘦肉PCOS的75%,超重对照的62%和超重PCOS的95%存在IR。瘦对照(平均?? SD; GIR 339 ?? 76 mg min-1 m-2)的IR低于瘦PCOS(270 ?? 66 mg min-1 m-2),超重对照(264 ?? 66 mg min) -1 m-2)和超重PCOS(175≤96 mg min-1 m-2)。在PCOS(y = 445.1-7.7x,R2 = 0.42(P <0.0001)中,GMI反映的BMI与IR之间的负相关比对照(y = 435.5-4.6x,R2 = 0.04(P <0.01))更明显局限性,需要谨慎的原因该研究没有使用葡萄糖示踪剂技术来完全表征IR,以及缺乏与人体组成和年龄相匹配的研究结果:s:BMI升高会加剧IR,从而支持内源性PCOS中的IR:不论内脏脂肪如何,BMI对PCOS中IR的影响均大于对照组,优先考虑生活方式干预以及需要有效的治疗干预措施来解决固有IR和预防糖尿病的高风险人群。 Interes:T(S)由研究人员启动的该试验得到了美国国家卫生与医学研究委员会(NHMRC)的资助号606553(HJT,NKS和SKH)以及莫纳什大学和让海尔斯基金会的资助。 NHMRC水库研究员。 N.K.S.由澳大利亚政府的合作研究网络(CRN)计划提供支持。 A.E.J.是Jean Hailes和NHMRC奖学金的持有人。作者声明与该手稿没有任何利益冲突。临床试验注册号84763265。 2013作者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号